Wealth Manager - the site for professional investment managers

Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.

Woodford plans to pour £30m into struggling Irish biotech firm

Woodford plans to pour £30m into struggling Irish biotech firm

Neil Woodford has expressed an interest in investing $50 million (£30 million) in an Irish biotech firm as part of a $100 million (£59 million) fundraising.

Prothena Corporation, a clinical stage biotechnology specialist focused on antibody development, is planning to use the proceeds for ongoing research and development purposes.

Shares in Prothena, which is headquartered in Dublin but traded on the Nasdaq, have plunged by 50% over the past three months after its latest trial data proved less positive than investors had hoped.

Despite this Prothena has reported a strong start to the year, with net income of $17.9 million (£10.5 million) in the first quarter compared with a net loss of $9 million (£5.3 million) in the equivalent period of 2013. It also has $195.1 million (£115 million) of cash on its balance sheet and no outstanding debt.

Citywire A-rated Woodford (pictured) has already begun populating his new fund’s portfolio with several other biotech businesses.

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.
Citywire TV
Play Big City Bright Future

Big City Bright Future

Big City Bright Future, the brainchild of BlackRock, is a three-week work experience programme for school leavers looking to forge a career in the City.

Play Kames' Ennett: Trump good for US high yield, but beware Europe

Kames' Ennett: Trump good for US high yield, but beware Europe

Kames Capital’s head of high yield David Ennett believes the changing political landscape will be a positive for the US, but negative for Europe in 2017.

Play Philip Milburn: why inflation won't run out of control

Philip Milburn: why inflation won't run out of control

Kames bond fund manager views inflation as more of 'scare' than a 'problem' and is positioning his portfolios accordingly.

Read More
Your Business: Cover Star Club

Profile: from Batman Live to commodity beta

Profile: from Batman Live to commodity beta

Charteris may be a family affair, but the company is not at any risk of turning sentimental

Wealth Manager on Twitter